Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
Open Access
- 1 April 2018
- journal article
- editorial
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 4 (2)
Abstract
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: The objective of this commentary is to propose a useful cost-effective disease-modifying treatment option for pwMS in LMIC with potential high efficacy and high convenience to the pwMS and treating physician. Viewpoint: We propose using generic 2-chloro-2’-deoxyadenosine (cladribine), a small molecule licensed for treatment of people with hairy cell leukaemia, as a solution of this significant equity imbalance. Cladribine has been shown in phase II and III trials to be a highly effective disease-modifying treatment for pwMS, and its adverse effect profile is comparable with any DMT currently licensed in high-income economies where an oral preparation has recently been licensed by the European Medicines Agency. Conclusion: Our viewpoint takes into account experience we have gathered over the past three years in the use of generic cladribine to treat pwMS. Whilst here we focus on MS, there is significant potential for use of cladribine in other conditions that could benefit from its mechanism of action.Keywords
Funding Information
- European Committee for Treatment and Research in Multiple Sclerosis (FS-ECTRIMS2016-0042; ECTRIMS Clinical Training Fel)
This publication has 40 references indexed in Scilit:
- Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisCochrane Database of Systematic Reviews, 2013
- Mitoxantrone-related acute leukemia in MSNeurology, 2013
- Cladribine tablets for the treatment of relapsing–remitting multiple sclerosisExpert Opinion on Pharmacotherapy, 2012
- Therapeutic Armamentarium and Health System Coverage of Multiple Sclerosis in Latin AmericaNeuroepidemiology, 2012
- Neurologic indications for therapeutic plasma exchange: 2011 updateJournal of Clinical Apheresis, 2012
- ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosisBrain, 2009
- Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover studyMultiple Sclerosis Journal, 2009
- Cyclophosphamide for multiple sclerosisCochrane Database of Systematic Reviews, 2007
- The Safety Profile of Low-dose Cladribine in Refractory Rheumatoid ArthritisScandinavian Journal of Rheumatology, 1997
- Cladribine in treatment of chronic progressive multiple sclerosisThe Lancet, 1994